Side-by-side · Research reference
LL-37vsP21
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED15/35 cited
BAnimal-MechanisticHUMAN-REVIEWED8/36 cited
LL-37
Cathelicidin · Human AMP
Broad-spectrumAntimicrobial activity
Endogenous · Secreted at inflammation sites
P21
CNTF-Derived Neuropeptide · Animal Model Evidence
Animal onlyEvidence level
SQ · Site unspecified · Frequency unknown
01Mechanism of Action
Parameter
LL-37
P21
Primary target
CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells
Pathway
hCAP-18 precursor → Proteinase-3 cleavage → LL-37 release → Membrane insertion/disruption
CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection
Downstream effect
Membrane permeabilization, cytokine induction, autophagy, phagosome-lysosome fusion, chemotaxisAhmad 2026Zhang 2026
Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders
Feedback intact?
—
—
Origin
Endogenous human cathelicidin (37-AA fragment, residues 134–170 of hCAP-18)
Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024
Antibody development
—
—
02Dosage Protocols
Parameter
LL-37
P21
Endogenous expression
Constitutive in neutrophils, epithelial tissues
Upregulated during infection and inflammation.Pinheiro 2026
—
Exogenous (experimental)
Dose varies by study; antimalarial ~10–50 μM in vitro
No FDA-approved exogenous formulation.
—
Plasma levels (malaria)
Elevated in infected patients and miceHe 2026
Exogenous administration reduced parasitemia in murine models.He 2026
—
Evidence basis
In vitro, animal models, human observational
Animal models only
CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024Cox 2026Jia 2020
Human dosing
—
No established protocol
No clinical trial data available.
Animal models (mice)
—
Dose and route not specified in abstractsMottolese 2024Jia 2020
In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.
Duration
—
Not specified
Route
—
Presumed subcutaneous or intraperitoneal (animal studies)
04Side Effects & Safety
Parameter
LL-37
P21
Cytotoxicity (high dose)
Membrane disruption in host cells at supraphysiological concentrations
—
Pro-inflammatory signaling
Can exacerbate inflammation in certain contexts (context-dependent)Pinheiro 2026
—
Theoretical cancer risk
Immunomodulatory roles in tumor microenvironment under investigation
—
Human safety data
—
None available
No clinical trials in humans.
Animal tolerability
—
Well-tolerated in mouse models; no toxicity reported in available abstracts
Theoretical risks
—
Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects
Absolute Contraindications
LL-37
—P21
- ·Use in humans not validated
Relative Contraindications
LL-37
- ·Active autoimmune disease (theoretical immune dysregulation)
P21
- ·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
- ·Pregnancy or lactation (no safety data)
05Administration Protocol
Parameter
LL-37
P21
1. Natural secretion
LL-37 is constitutively expressed in neutrophils and epithelial cells, cleaved from hCAP-18 by proteinase-3 at sites of infection or inflammation.
Not established. No FDA approval, no clinical trial data.
2. Experimental formulations
Synthetic LL-37 and derivatives (e.g., SAMP-12aa) tested in vitro and animal models. Administered via topical, intraperitoneal, or intravenous routes in research settings.
In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.
3. Stability considerations
LL-37 is resistant to pepsin degradation at gastric pH. Synthetic short peptides designed to retain this stability while reducing toxicity.Lu 2026
—